Return to Skip Menu

Main Content

Key protein molecule linked to diverse human chronic inflammatory diseases


BLACKSBURG, Va., Sept. 25, 2008 – Liwu Li, associate professor of biological sciences at Virginia Tech, has revealed a common connection between the cellular innate immunity network and human chronic inflammatory diseases, including atherosclerosis, Type 2 Diabetes, and neurodegenerative diseases. The finding presents a viable cellular and molecular target for the diagnosis and treatment of serious human inflammatory diseases, according to Li.

“Researchers and physicians have long recognized that there is an association between these conditions. For example, obesity increases the risk of heart attack or stroke, Type 2 Diabetes or insulin resistance, and Alzheimer’s Disease,” said Li, who is the founding director of the Inflammation Center at Virginia Tech.

“Inflammation is the common mechanism,” he said. “Inflammation is a double-edged sword. Proper inflammation is necessary to fend off infection and abnormal cell growth. On the other hand, excessive inflammation contributes to diverse chronic diseases, including atherosclerosis, diabetes, and lupus.” However, the complex cellular and molecular networks controlling inflammation are still poorly understood, he said. “The lack of understanding impedes our progress in treating serious chronic inflammatory diseases.”

In a series of studies published throughout the last decade*, Li’s group has defined several critical signaling networks essential for the modulation of inflammation. In particular, a key cellular protein kinase named interlukin-1 receptor associated kinase 1 (IRAK-1) was shown to be critical for processing diverse inflammatory signals, including microbial products, cytokines, and insulin. Li’s group discovered that excessive IRAK-1 activation is linked with the risk of atherosclerosis and diabetes. Using transgenic mice without the IRAK-1 gene, Li’s group demonstrated that IRAK-1 deficient mice are protected from developing atherosclerosis and insulin resistance.

At the molecular level, Li’s laboratory discovered that IRAK-1 prefers to phosphorylate transcription factors harboring the Serine-Proline motif including STAT-3 and NFAT. Subsequently, STAT-3 and NFAT are involved in modulating the expression of distinct inflammatory mediators responsible for the excessive activation of specialized macrophages and T cells. These cells eventually contribute to diverse inflammatory symptoms including cardiovascular diseases, diabetes, Alzheimer’s diseases, and lupus. “Chemical compounds targeting this molecule will have enormous therapeutic potential,” Li said.

“There is still a long way to go for finding the actual cure for these diseases,” he said. “That is why we are combining expertise from various disciplines, including experimental biology and computational simulation. The Inflammation Center integrates faculties with expertise in experimental molecular biology, cutting edge imaging of inflamed cells and tissues, computational simulation of cellular signaling networks, human and animal studies, and nano-technologies designing novel intervention.”

Virginia Tech Intellectual Properties Inc. (VTIP) filed a patent application for Li’s discovery and its use as a diagnostic tool and treatment strategy. “This technology will still take some time before there is a product,” said Li.

“But it is an important piece of intellectual property that will benefit from the increased emphasis on human health that is taking place at Virginia Tech now through the Virginia Tech Carilion Medical Research Institute and its partnerships with physicians,” said Jackie Reed, licensing associate with Virginia Tech Intellectual Properties.

Li also points out that the medical students from the new medical school will benefit from his research. In turn, he will have the opportunity to gain clinical samples from physicians at Carilion. “The goals of translating basic findings into future therapies will be reached more easily through our collaborations with clinical physicians,” said Li.

“The Virginia Tech-Carilion partnership in the medical school is going to accelerate the translational research process -- moving important basic science research to the bedside,” said Reed.

Li’s research is funded by major research grants from the National Institutes of Health.

Inflammation is one of four initial research areas for the Virginia Tech Carlion Medical Research Institute. The others are cardiovascular science and cardiology, neuroscience, and infectious disease. The medical research institute, managed by Virginia Tech, is a collaboration with the Carilion Clinic and the newly established Virginia Tech Carilion School of Medicine, a private independent school jointly managed by Virginia Tech and Carilion, all co-located on a new campus under construction in Roanoke.

*The most recent publication from Li’s group appeared in the September 2008 issue of Molecular Immunology, “The interleukin-1 receptor associated kinase 1 contributes to the regulation of NFAT,” by Dongmei Wang, Stephan Fasciano, Liwu Li (available online Aug. 8, 2008.), pages 3902-3908.

Listen to the related podcast. (Length 0:53)